Hanna Ljung

Hanna Ljung

Auto-generated profile, based on publicly available information

Hanna Ljung

Division of Neurology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 December 2024 in Drug Safety
Verified
Journal Article
Open access
PDF file
ARArne Reimers
Arne Reimers
POPer Odin
Per Odin
HLHanna Ljung
Hanna Ljung
Drug-induced cognitive impairment (DICI) is a well-established, yet under-recognised, complication of many types of pharmacological treatment. While there is a large body of scientific literature on DICI, most papers are about drug-induced dementia in the elderly and one specific drug class. However, DICI also comprises subclinical symptoms, domain-specific forms of cognitive impairment as well as mild cognitive impairment (MCI), and delirium. Even mild forms of DICI, if not recognised as such, can have deleterious and life-long consequences. In addition, DICI also occurs in younger adults and in children, and has been reported with many different drug classes. The aim of this review is to raise awareness of DICI by providing an overview on the type(s) and symptoms of observed DICI and the suspected underlying mechanism(s) for various drug classes: antiseizure medications, antidepressants, antiparkinsonian drugs, antipsychotics, lithium, benzodiazepines/Z-drugs, opioids, first-generation antihistamines, drugs for urinary incontinence, proton pump inhibitors, glucocorticoids, NSAIDs, statins, antihypertensives, and chemotherapeutic agents.

25 March 2019 in Expert Opinion on Pharmacotherapy
Verified
Journal Article
Open access
ARArne Reimers
Arne Reimers
HLHanna Ljung
Hanna Ljung
Introduction: About 70 million people worldwide are estimated to suffer from epilepsy. Despite a large variety of old and new antiepileptic drugs on the market, about 30% of people with epilepsy do not become seizure-free with medical treatment. This is a major individual and public health burden. Most of these difficult-to-treat patients are having focal seizures. Zonisamide is effective against focal seizures in adults and children and, thus, a therapeutic option for such patients. Its safety profile needs special attention. Areas covered: Herein, the authors discuss the pharmacology, clinical efficacy and the adverse effects of zonisamide. The article is derived from clinical trial data, long-term studies, meta-analyses, review articles, text books, webpages, and official license information. Expert opinion: Zonisamide has proven to be efficacious in focal epilepsy in children and adults, although it is not more effective than carbamazepine or other antiepileptic drugs. It is also effective in generalized epilepsy and in several other conditions of the CNS. Its safety profile may prevent it from becoming a first-line drug for focal epilepsy or any other indication.

16 November 2023 in Drug Safety
Verified
Journal Article
Open access
PDF file
ARArne Reimers
Arne Reimers
HLHanna Ljung
Hanna Ljung
Background and Objective The number of reports on suspected drug-induced memory impairment submitted to the US Food and Drug Administration increased 30-fold from 2000 to 2022. Drugs are the most common cause of reversible dementia. However, there is very little research on drug-induced cognitive impairment. The aim of this study was to investigate if and how an assessment of cognitive safety was included in recent, registered, controlled, clinical drug trials. Methods The clinical trials registry (www.clinicaltrials.gov) was searched for randomized controlled clinical trials with available study protocols. After excluding irrelevant trials such as surgical procedures, local or short-term treatment, and dietary supplements, 803 trials were included in this study. The protocols were manually reviewed for information on if, and how, cognitive safety had been assessed. Trial drugs were categorized into those targeting the central nervous system or not, as well as older and newer drugs. Methods used for the assessment of cognitive function were categorized into questionnaires, screening instruments, and neuropsychological tests. If the trial results were published, we examined whether the publication contained any data on cognitive safety that had emerged from the trial. Results The start dates of the screened trials ranged from 31 July, 2009, to 4 April, 2021. Out of the 803 trials, 52 (6.5%) actively assessed cognitive safety. The remaining trials relied solely on spontaneous reporting. Of 429 trials studying a new drug, 32 (7.5%) actively assessed cognitive safety. One hundred and fifty-eight trials examined drugs intended to, or known to have, pharmacological effects on the central nervous system. Of these, 21 (13.5%) assessed cognitive safety. Most of the trials that assessed cognitive safety used either crude screening tools or questionnaires. Conclusions Cognitive safety is largely ignored by recent controlled clinical trials. This applies even to trials assessing new drugs and trials assessing central nervous system drugs. There is an urgent need for drug manufacturers, regulatory authorities, and the medical profession to address the cognitive safety of drugs.

1 November 2023 in Journal of the International Neuropsychological Society
Verified
Journal Article
Open access
PDF file
ENErik Blennow Nordström
Erik Blennow Nordström
SVSusanna Vestberg
Susanna Vestberg
LELars Evald
Lars Evald
Marco MionMarco Mion
Marco Mion
MSMagnus Segerström
Magnus Segerström
GLGisela Lilja
Gisela Lilja
Objective: To describe cognitive impairment in out-of-hospital cardiac arrest (OHCA) survivors, with the hypothesis that OHCA survivors would perform significantly worse on neuropsychological tests of cognition than controls with acute myocardial infarction (MI). Another aim was to investigate the relationship between cognitive performance and the associated factors of emotional problems, fatigue, insomnia, and cardiovascular risk factors following OHCA.Participants and Methods: This was a prospective case control sub-study of The Targeted Hypothermia versus Targeted Normothermia after Out-of-Hospital Cardiac Arrest (TTM2) trial. Eight of 61 TTM2-sites in Sweden, Denmark, and the United Kingdom included adults with OHCA of presumed cardiac or unknown cause. A matched non-arrest control group with acute MI was recruited. We administered an extensive neuropsychological assessment at approximately 7 months post-cardiac event, including a neuropsychological test battery and questionnaires on anxiety, depression, fatigue, and insomnia, and collected information on the cardiovascular risk factors hypertension and diabetes. Z-scores of individual tests were converted to neuropsychological composite scores per cognitive domain (verbal, visual/constructive, working memory, episodic memory, processing speed, executive functions). Between-group differences on the neuropsychological composite scores were investigated with linear regression. Associations between anxiety, depression, fatigue, insomnia, hypertension, diabetes, and the neuropsychological composite scores among OHCA survivors were calculated with Spearman’s rho.Results: Of 184 eligible OHCA survivors, 108 were included (mean age = 62, 88% male), with 92 MI controls enrolled (mean age = 64, 89% male). Amongst OHCA survivors, 29% performed z <-1 indicating at least borderline-mild impairment in >2 cognitive domains, and 14% performed z <-2 exhibiting major impairment in >1 cognitive domain. OHCA survivors performed significantly worse than MI controls in episodic memory (mean difference, MD = -0.37, 95% confidence intervals [-0.61, -0.12]), verbal (MD = -0.34 [-0.62, -0.07]), and visual/constructive functions (MD = -0.26 [-0.47, -0.04]) on linear regressions adjusted for educational attainment and sex. When additionally adjusting for anxiety, depression, fatigue, insomnia, hypertension, and diabetes, processing speed (MD = -0.41 [-0.74, -0.09]) and executive functions (MD = -0.69 [-1.13, -0.24]) were also worse following OHCA. Depressive symptoms were associated with worse executive functions (rs = -0.37, p <0.001) and worse processing speed (rs = -0.27, p = 0.01) post-OHCA. Anxiety symptoms (rs = -0.21, p = 0.01) and general fatigue (rs = -0.24, p = 0.01) were associated with worse executive functions. Diabetes was associated with worse processing speed (rs = -0.20, p = 0.03), visual/constructive (rs = -0.29, p <0.001) and executive functions (rs = -0.25, p = 0.02), while hypertension and insomnia were not significantly associated with neuropsychological test performance.Conclusions: Cognitive impairment is generally mild following OHCA, but most pronounced in episodic memory, executive functions, and processing speed. OHCA survivors performed worse than MI controls. We suggest that a post-OHCA follow-up service should screen for cognitive impairment, emotional problems, and fatigue.


1 January 2025 in Parkinson's Disease
Verified
Journal Article
Open access
MSMonica Scharfenort
Monica Scharfenort
VHVeronica Hernström
Veronica Hernström
KRKristina Rosqvist
Kristina Rosqvist
HLHanna Ljung
Hanna Ljung
MNMaria H Nilsson
Maria H Nilsson
POPer Odin
Per Odin
Background: It is unclear whether the two device‐aided therapies (DATs: deep brain stimulation [DBS] and levodopa–carbidopa intestinal gel [LCIG]) affect personality in patients with Parkinson’s disease (PD). Objective: This retrospective study aims to explore if patients with PD and their close relatives experience any changes in the patient’s personality following the start of DAT. Methods: In total, 32 patients with DAT (17 DBS and 15 levodopa pump–based therapy) and their close relatives ( n = 32) were asked to retrospectively assess potential personality changes in the patients using the Big Five Inventory (BFI) following DAT. They also answered questions regarding perceived quality of life and perceived impact on motor symptoms. Results: There was a diverse perceived change in the patients’ five personality traits when divided into the type of therapy. DBS patients reported decreased extraversion (70.6%, n = 12), while their close relatives reported an increase in the trait neuroticism (82.4%, n = 14). A significant difference was found in perceived changes in agreeableness, with 8 DBS patients reporting an increase and 4 close relatives reporting a decrease ( p = 0.008). Most of the pump patients (LCIG) reported a decreased conscientiousness (66.7% n = 10), a perception confirmed by 73.3% ( n = 11) of their close relatives, who in addition reported an increase in neuroticism (73.3%, n = 11). Conclusions: This study suggests perceived personality changes following DAT (DBS or LCIG), which vary by therapy and respondent role. Larger studies are needed, but the findings signal the importance of considering both patients’ and their relatives’ perspectives when assessing personality changes.